Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Study of Olaparib With Sapacitabine in BRCA Mutant Breast Cancer

Trial Profile

A Phase Ib/II Study of Olaparib With Sapacitabine in BRCA Mutant Breast Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olaparib (Primary) ; Sapacitabine (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 May 2019 According to a Cyclacel Pharmaceuticals media release, three patients have been dosed. The first two achieved tumor shrinkage and continue on treatment and the third has completed first cycle without dose-limiting toxicity.
    • 27 Mar 2019 According to a Cyclacel Pharmaceuticals media release, the first two patients have been dosed in the trial. Patient enrolment has continued in part 3 of a Phase 1 study evaluating a revised dosing schedule of sequential sapacitabine and seliciclib, in BRCA mutation positive patients with advanced breast, ovarian and pancreatic cancer. New data on an expanded cohort from part 1 will be presented at the 2019 AACR.
    • 07 Jan 2019 According to a Cyclacel Pharmaceuticals media release, initial data readout is expected in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top